Concurrent facial and trigeminal nerve palsies in a child following COVID-19 vaccination with the Pfizer vaccine.
Carine J MoeziniaEleanor B HarbinsonRobert M MaweniPublished in: BMJ case reports (2023)
We present the case of a teenaged boy who attended our Ear, Nose and Throat Emergency clinic with a left-sided lower motor neuron (LMN) facial nerve paralysis associated with sensory loss in the distribution of the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve. This happened 3 days following a first dose of the Pfizer-BioNTech BNT162b2 vaccine. He had a House-Brackmann grade V facial palsy, with marked inability to close the left eye. He was treated with a 10-day course of oral steroids and referred to ophthalmology for eye care. He had an MRI scan of the head, which revealed no space occupying lesions or other abnormalities. Over the 6-week period of follow-up, the patient's V1 and V2 sensation gradually resolved, along with improvement of his LMN facial nerve palsy to House-Brackmann grade 3. Despite the potential temporal relationship, it is not possible to establish a causal relationship between the patient's symptoms and the Pfizer-BioNTech BNT162b2 vaccine, thus further research is required.
Keyphrases
- peripheral nerve
- soft tissue
- healthcare
- coronavirus disease
- case report
- sars cov
- public health
- computed tomography
- emergency department
- magnetic resonance imaging
- mental health
- neuropathic pain
- primary care
- palliative care
- randomized controlled trial
- contrast enhanced
- clinical trial
- single cell
- pain management
- risk assessment
- radiation therapy
- quality improvement
- spinal cord injury
- study protocol
- spinal cord
- newly diagnosed
- machine learning
- optic nerve
- sleep quality
- affordable care act